1646 results about "Methylation" patented technology

The invention provides a protein methylation site prediction method fusing quantum and region perception, which comprises the following steps: step 1, acquiring a protein sequence as a data source, and respectively constructing a training set and an independent test set; 2, constructing a multi-modal feature for each protein sequence by adopting a three-way nested scattering network, and fusing the multi-modal features to obtain an optimized fusion feature tensor; and step 3, inputting the optimized fusion feature tensor into a RaQMeNet network model, and performing a methylation site prediction task. The performance indexes of the method are greatly superior to those of the prior art, and the method has higher adaptability, stability and interpretability, can be widely applied to a plurality of bioinformatics and biological medicine related fields such as protein function annotation, disease mechanism research and drug target discovery, and has good application prospects and commercial values.

The invention discloses a synthetic method of a water soluble ultraviolet light absorber BP-9. The method mainly comprises the following process steps: (1) carrying out methylation on the main raw materials of 2, 2', 4, 4'-tetrahydroxyl benzophenone, a transition metal salt catalyst and a mixed solvent which is prepared from dichloroethane and anhydrous ethanol in equal parts by weight to obtain 2, 2'-dihydroxyl-4, 4'-dimethoxyl benzophenone; (2) carrying out sulfonation reaction on the main raw materials of methylate, sulfamic acid and C1-C3 halohydrocarbon to obtain 2, 2'-dihydroxyl-4, 4'-dimethoxyl benzophenone-5, 5'-disulfonic acid; and (3) carrying out neutral reaction on the main raw materials of sulfonated product, inorganic base and ethanol water to finally obtain the BP-9 product. The synthetic method disclosed by the invention is few in reaction step, low in cost, high in product purity and stable in quality, and raw materials are easily available.

Disclosed herein are methods, compositions, and devices for use in diagnosis and treatment of cancer. The methods include sequencing a panel of regions in cell-free nucleic acid molecules and detecting one or more biomarkers that are indicative of a cancer.

The invention provides a methylation detection combined marker based on free DNA (cfDNA) in pulmonary alveolar lavage fluid (BAL) and application of the methylation detection combined marker. The methylation combination marker optimizes methylation detection targets in early screening of lung cancer, reduces detection difficulty and cost, and has high diagnosis accuracy, sensitivity and specificity.

The invention relates to a methylation biomarker for detecting colorectal cancer or colorectal adenoma. The methylation biomarker comprises any one gene of SDC2, COL4A2 and C9H9orf50 or any combination of the SDC2, the COL4A2 and the C9H9orf50. Wherein a methylation target detection region of the SDC2 gene is a full-length region of chr8: 96494012-96494130 or a partial region of the full-length region of chr8: 96494012-96494130; a methylation target detection region of the COL4A2 gene is a full-length region of chr13: 110306814-110306983 or a part of the full-length region of the chr13: 110306814-110306983; and the methylation target detection region of the C9H9orf50 gene is the full-length region of chr9: 129620291-129620374 or a part of the full-length region of chr9: 129620291-129620374. According to the kit, methylation signals related to intestinal cancer and adenoma in excrement samples can be more accurately detected through detection in different combination modes of the three markers, the early effective diagnosis rate of colorectal cancer patients can be increased, and therefore the survival rate of the patients is increased, and prognosis is improved.

The invention provides an individualized management system and method for colorectal cancer risk prediction, and relates to the technical field of medical diagnosis and individualized medical treatment. The system comprises a multi-omics data processing module used for collecting a blood sample of a subject, extracting circulating free DNA, and sequencing cfDNA by adopting a simplified methylation sequencing technology to obtain final original data of DNA methylation characteristics; the risk prediction module is used for carrying out bioinformatics analysis on the original data of the final DNA methylation features by adopting a machine learning algorithm, extracting a methylation feature set, a tail end motif feature set and a breakpoint motif feature set, and carrying out risk prediction on the basis of the extracted feature sets; and predicting the colorectal cancer disease risk of the subject by using a pre-trained prediction model to obtain a prediction result. The problem that the risk prediction accuracy of the colorectal cancer is low is solved.

The present disclosure relates to compositions and methods for reducing expression of MYC gene in a cell. In some embodiments, an expression repressor comprises a targeting moiety that binds a MYC promoter, anchor sequence, or super-enhancer. In some embodiments, the expression repressor comprises an effector moiety that represses transcription or methylates DNA. Systems comprising two expression repressors are also disclosed. The compositions can be used, for example, to treat cancers such as HCC.

The invention relates to a method for carrying out pathogenic microorganism identification and gene variation state joint detection on a pulmonary alveolar lavage fluid sample based on high-throughput sequencing. The method comprises the following steps: extracting nucleic acid from the pulmonary alveolar lavage fluid sample; constructing a metagenome capture library, and constructing a lung cancer polygene library; carrying out final library pooling; performing high-throughput sequencing; and analyzing data. Compared with the prior art, the scheme provided by the invention is based on a technical path of'macro 'captured by metagenome and'target' of targeted high-throughput sequencing; after the constructed final library is subjected to high-throughput sequencing and data analysis, index output (pathogenic microorganism identification, host chromosome copy number variation, gene mutation, gene fusion, gene copy number variation and methylation state) of multiple biomarkers can be met in one-time detection.

The present invention provides for novel methods for regulating and detecting the cytosine methylation status of DNA. The invention is based upon identification of a novel and surprising catalytic activity for the family of TET proteins, namely TET1, TET2, TEM3, and CXXC4. The novel activity is related to the enzymes being capable of converting the cytosine nucleotide 5-methylcytosine into 5-hydroxymethylcytosine by hydroxylation.

The application provides a novel DNA methylation marker TAGMe-3 for tumor identification and use thereof. The TAGMe-3 gene sequence region has significant methylation difference between cancer tissues and paracancer tissues. As long as abnormal high methylation state of the TAGMe-3 gene sequence region is detected, the subject is determined to belong to a tumor high-risk population. Moreover, the significant difference of the TAGMe-3 presented between tumor tissues and non-tumor tissues exists in different types of tumors (Pan-cancer) in a wide range.

The present technology relates to a method of treating one or more symptoms of Full Methylation (Fmet) Fragile X Syndrome in a subject that includes administering an effective amount of cannabidiol to the subject such that one or more symptoms of Fragile X Syndrome are treated.

The invention discloses a method for screening and identifying a cucumber aphid-resistant gene as well as a screened gene and application thereof, and provides a brand-new method for screening and identifying the cucumber aphid-resistant gene, which is used for screening the cucumber aphid-resistant gene based on four omics technologies. The four types of omics comprise transcriptome, proteome, methylation group and metabolome before and after inoculation of aphids on cucumbers, and the cucumber aphid resistance regulation gene is screened through combined analysis, so that a new gene resource is provided for improving the aphid resistance of the cucumbers, and a new method and a new idea are provided for designing molecular genetic breeding. The CsPGD2 gene obtained through screening is an aphid resistance gene, the dynamic change of a metabolic substance 5-ribulose phosphate in a metabolome is consistent with that of a transcriptome gene CsPGD2, the aphid resistance function of the gene CsPGD2 is verified through VIGS, and the result proves that the gene CsPGD2 is an important regulation factor for the aphid resistance of cucumbers. The invention provides a new gene resource for improving the aphid resistance of cucumbers, and has a good application prospect.

The invention relates to the technical field of cancer risk prediction, in particular to a deep learning cancer risk prediction method and system based on a methylation sequence. The method comprises the following steps: acquiring DNA methylation sequencing data and reference genome annotation data in a blood sample of a cancer patient; performing functional region classification processing on the DNA methylation sequencing data according to the reference genome annotation data to obtain promoter subregion methylation data, enhancement subregion methylation data and transcription factor binding site methylation data; performing dynamic sequence similarity calculation processing on the methylation data of the promoter region to obtain a first feature vector containing importance weight of the promoter region of the cancer-related gene; the methylation sites are classified according to the functions of the methylation sites in the transcriptional regulation pathway, so that the biological interpretation of the characteristics is improved, and the synergistic effect among different functional regions can be captured.

The invention belongs to the technical field of biological diagnosis, and particularly relates to application of a reagent for detecting DNA methylation of an RPL10 promoter region in preparation of a sow pregnancy diagnosis product. Through methylation high-throughput sequencing of blood DNA of pregnant sows and non-pregnant sows, it is found that the methylation level of a gene promoter region of the ribosomal protein L10 in the early pregnancy stage of the sows is remarkably reduced. The methylation level of the pregnant sow RPL10 is analyzed by using MSP, BSP and qMSP methods, and meanwhile, the ROC curve analysis result also shows that the RPL10 has diagnostic value. The results show that the method for detecting the RPL10 gene in the pig blood sample can be an effective method for diagnosing the early pregnancy of pigs. According to the invention, a pregnancy diagnosis technology based on RPL10 promoter region DNA methylation is preliminarily established, pig pregnancy detection methods are enriched, and a reference is provided for further exploring the DNA methylation level and the regulation mechanism of the pig pregnancy early stage.

Compositions and methods for profiling methylation patterns present on target DNA in solution or affixed to a solid support are disclosed using enzymatic deamination-resistant and optionally also chemically resistant, oligonucleotides and nucleotides.

The invention relates to the technical field of tumor data processing, in particular to a methylation-based tumor data processing system. The system comprises the following modules: a methylated sample sequencing module, a sequencing difference site recognition module, a tumor gene sequence analysis module and a tumor subtype classification module, performing high-throughput sequencing on the to-be-detected clinical tumor DNA sample to obtain methylated tumor sequencing data; performing methylation level quantification on the methylated tumor sequencing data, and performing tumor difference site analysis to generate tumor difference site data; performing tumor generation key gene sequence identification according to the tumor difference site data to generate tumor methylation characteristic data; and performing tumor subtype tag identification according to the tumor methylation characteristic data to generate tumor type tag data. According to the method, accurate tumor typing is realized on the basis of tumor DNA methylation characteristic analysis, and the false negative rate of low-concentration sample detection is effectively reduced.

The present disclose provides a method for classifying a sample derived from a subject. The method may comprise obtaining a sample comprising nucleic acid molecules from the subject. The method can comprise assaying the nucleic acid molecules to generate a data set comprising methylation states of one or more genomic regions. The one or more genomic regions can comprise differentially methylation regions (DMRs). The method can comprise processing at least a portion of the data set to generate an output indicative of cancer in the subject. The portion of the data set can pertain to a set of DMRs specific to the subject.

The invention discloses a methylated biomarker for detecting esophageal cancer and application of the methylated biomarker. The invention provides a methylated biomarker, and the methylated biomarker comprises any one selected from the following differential methylated regions or any combination of the differential methylated regions: chr17: 49021947-49022096, chr19: 11998652-11998772, and the like. The invention also provides a method for preparing the methylated biomarker, and the methylated biomarker comprises any one selected from the following differential methylated regions: chr17: 49021947-49022096, chr19: 11998652-11998772, and the like. The methylated biomarker provided by the invention can be used for diagnosing esophageal cancer, and has good sensitivity, specificity and accuracy.

The present invention discloses a cell-labeling microbead, a preparation method and an application thereof, relating to the field of biological detection. The cell-labeling microbead includes a microbead, a universal primer sequence, a cell label and a linking sequence that are sequentially coupled to the microbead; wherein, the universal primer sequence is used to bind to a primer compatible with a sequencer, and dC in the universal primer sequence is 5-Methyl dC; the cell label is used to trace and identify target cells, and the bases in the cell label include A base, T base, G base; the linking sequence is used to link the cell label to the target cells. The technical solution of the present invention avoids base conversion by removing unmethylated C bases in the universal primer sequence and the cell label sequence, and realizes the construction of a high-throughput single-cell DNA methylation library; by labeling multiple sequences on the microbead, the number of primer syntheses and costs are significantly reduced, which helps to promote the development and application of high-throughput sequencing technology for single-cell DNA methylomes.

The invention discloses a method for predicting an RNA (Ribonucleic Acid) methylation site, which is based on a multi-modal feature fusion and semantic vector embedding technology and is used for remarkably improving the recognition precision of an m7G modification site. The method comprises the following steps: firstly, constructing an RNA sequence data set containing positive and negative samples, and dividing the RNA sequence data set into a training set and an independent test set according to a predetermined proportion; then, multi-modal features are extracted through One-hot coding (One-hot), nucleotide chemical property coding (NCP), electron-ion interaction potential coding (EIIP) and local nucleotide composition coding (ENAC), and context semantic information of a nucleotide sequence is obtained in combination with a DNA2Vec model; according to the model, a multi-modal feature fusion path (MRF) and a DNA2Vec embedding path are adopted, after feature dimension compression is carried out through a full connection layer, a Transform encoder is used for capturing a long-range dependency relationship, and a prediction probability is calculated through a Sigmoid activation function. In the optimization process, batch normalization, Dropout and Adam optimizers are adopted, and the binary cross entropy loss function is minimized. Finally, the performance of the model is evaluated through five-fold cross validation, and the generalization ability of the model is verified on an independent test set. According to the method, through multi-source feature fusion and hierarchical modeling, the analysis capability of sequence information is remarkably improved, and an accurate calculation tool is provided for RNA modification prediction.

The invention discloses immobilized lipase based on bifunctional silicon dioxide as well as a preparation method and application of the immobilized lipase. Hydrophobic modification and covalent modification are performed on the surface of mesoporous silicon dioxide to obtain a bifunctional silicon dioxide carrier; the hydrophobic modification is any one of methylation modification, octylation modification, octadecyl alkylation modification, esterification modification and bromopropylation modification. The dual-functionalized silicon dioxide carrier is used for immobilization of lipase, and the prepared immobilized lipase can be used for production of biodiesel. The immobilized lipase provided by the invention is mild in enzyme reaction condition, good in biocompatibility, relatively high in enzyme activity, and excellent in stability and repeatability. In addition, by changing the ratio of the covalent modifier to the hydrophobic modifier, the catalytic activity and stability of the immobilized enzyme and the biodiesel yield are remarkably improved.

The invention discloses application of decitabine in preparation of a medicine for resisting vascular calcification, and belongs to the technical field of medical biology. A CKD mouse vascular calcification model is constructed through combination of 5 / 6 nephrectomy and high phosphorus diet (5 / 6NX), and it is observed that the expression level of DNMT3A in model mouse calcified blood vessels is remarkably increased, and the DNA methylation degree is remarkably increased. Based on this, people try to use decitabine to reduce the expression of DNMT, and discover that intraperitoneal injection of decitabine inhibits the expression of DNMT3A in CKD artery blood vessels and osteogenesis-like transdifferentiation of vascular smooth muscle cells, so that CKD-related vascular calcification is effectively relieved.

The invention relates to the field of anti-tumor drugs, and discloses an anti-diffuse large B-cell lymphoma pharmaceutical composition, a preparation method and application thereof, the composition comprises azacitidine and Sanilisoma, the composition can improve the accumulation amount of VDUP1 protein in a cell nucleus through the combination of the methylation effect of DNMT3b on VDUP1 protein and the inhibition of XPO1 activity by Sanilisoma, and the anti-diffuse large B-cell lymphoma pharmaceutical composition can be used for preparing anti-diffuse large B-cell lymphoma. The chemotherapy effect is remarkably improved, the sensitivity of the DLBCL to the Sanisole is remarkably improved, and particularly, the pharmaceutical composition has a remarkable curative effect on R / R DLBCL patients.

The present disclosure includes, among other things, methods, kits, and systems for determining the status of lung cancer. In various embodiments, the present disclosure relates to the use of one or more histone modifications, chromatin accessibility, binding of one or more transcription factors, and / or DNA methylation that that are characteristic of the status of lung cancer. In some embodiments, differential modifications and / or differential accessibility are detected and quantified at one or more genomic loci of a biological sample, e.g., in cell-free DNA (cfDNA) from a liquid biopsy sample obtained or derived from a subject with lung cancer. In various embodiments a determined status is useful, e.g., in selecting treatment for and / or treating a lung cancer.

Disclosed herein, inter alia, are compositions, methods, and kits useful for detecting nucleobase modifications on one or both strands of a double-stranded nucleic acid fragment.

The present disclosure includes, among other things, methods, kits, and systems for determining HER2 status of cancer, e.g., a breast, gastric / gastroesophageal, colorectal, or lung cancer. In various embodiments, the present disclosure relates to the use of one or more histone modifications, chromatin accessibility, binding of one or more transcription factors, and / or DNA methylation that that are characteristic of HER2 status of cancer. In some embodiments, differential modifications and / or differential accessibility are detected and quantified at one or more genomic loci of a biological sample, e.g., in cell-free DNA (cfDNA) from a liquid biopsy sample obtained or derived from a subject with cancer. In various embodiments a determined HER2 status is useful, e.g., in selecting treatment for and / or treating a cancer, e.g., a breast, gastric / gastroesophageal, colorectal, or lung cancer.

The invention discloses application of a Lys35 site of a PC4 protein as a target spot in preparation of tumor diagnosis and treatment products. The invention provides application of a Lys35 site of a PC4 protein as a target spot in preparation of a tumor diagnosis product. The research shows that the Lys35 site methylation of the PC4 protein can promote the cell cycle progress of tumor cells and promote the proliferation growth and malignant progression of the tumor cells, and the scheme for inhibiting the site methylation can be used for developing tumor treatment drugs. Therefore, the Lys35 site of the PC4 protein can be used as a key target to be applied to development of tumor diagnosis products and targeted therapy drugs. The invention further develops the PC4 protein Lys35 methylation antigen peptide and the antibody capable of specifically recognizing the PC4 protein Lys35 methylation site, and the PC4 protein Lys35 methylation antigen peptide and the antibody can be applied to regulation and control of tumor cell proliferation or growth, can be used for developing diagnostic products and targeted therapy drugs for clinical tumor diseases, and have good clinical application value.

The invention relates to the technical field of anti-tumor, in particular to a supramolecular assembly, a preparation method thereof and application of the supramolecular assembly in preparation of anti-tumor drugs. According to the present invention, tetraphenylporphyrin (TPP-Lys and TPP-Gln) modified by lysine and glutamine respectively and fully methylated cyclodextrin (Bio-PMeCD) modified by biotin are adopted as a carrier and a targeting agent to construct an assembly, and the assembly is used for intracellular enzymatic in-situ polymerization reaction, such that the application of the assembly in the aspects of photosensitizer retention time prolonging and photodynamic treatment effect improving is achieved.

The invention relates to the technical field of medical care informatics, in particular to a cancer type prediction method and system based on methylation data. The method comprises the following steps: acquiring whole genome methylation data of a sample; performing layering processing based on an epigenome functional region on the whole genome methylation data to obtain functional region layering data; according to the layered data of the functional regions, constructing a local methylation topological mode in each functional region to obtain a local methylation topological representation, the local methylation topological mode comprising a methylation space gradient, a methylation curvature feature and a region methylation entropy; mapping of methylation mode variable coefficients among different cell types is carried out according to local methylation topological representation, and a regional methylation stability index is obtained through calculation. According to the method, functional region layering and local topology construction are performed on methylation data, so that the regulation state of each functional region in the genome can be reflected more finely.

The invention discloses a Nur77 methylation site mutation peptide based on structural modification design and application of the Nur77 methylation site mutation peptide in promoting embryo implantation, according to the mutation peptide, arginine at the 346th site of Nur77 is mutated into lysine, and methylation modification of Nur77 is reserved while phosphorylation of Nur77 is inhibited, so that the transcriptional activity of Nur77 is enhanced. It is found that the mutant peptide can promote deciduation of endometrial interstitial cells, remarkably improve deciduation disorder of infertility mice in in-vivo experiments and improve the embryo planting rate of low-fertility mice. Therefore, the mutant peptide is expected to become a new medicine for treating the uterine-derived infertility and has important clinical application value. The invention also relates to a preparation method of the mutant peptide and application of the mutant peptide in a pharmaceutical composition and a treatment method.